FDA Recalls Generic Zyrtec Over Zantac Contamination
The FDA has issued a recall for generic Zyrtec manufactured by Unique Pharmaceutical Laboratories due to contamination with Zantac. The recall was announced by KSTP.com 5 Eyewitness News, referencing an FDA announcement.
Minneapolis St. Paul, MN, July 22, 2026 —
The U.S. Food and Drug Administration (FDA) has initiated a recall for a specific batch of generic Zyrtec, a popular allergy medication. The recall is due to the presence of Zantac, a different medication, found as a contaminant. Unique Pharmaceutical Laboratories is the manufacturer of the affected generic Zyrtec product.
The announcement regarding this recall was made by KSTP.com 5 Eyewitness News. This news outlet cited an official announcement from the FDA as the source of the information.
Details regarding the specific lot numbers or expiration dates of the recalled generic Zyrtec were not immediately available in the provided information. The nature and extent of the Zantac contamination were also not specified. Consumers who may have purchased this product are advised to check for any recall notices from the manufacturer or the FDA.
Zantac, also known by its generic name ranitidine, was previously subject to recalls due to the presence of N-nitrosodimethylamine (NDASA), a probable human carcinogen. The contamination issue with Zantac led to its widespread removal from the market.
The reason for Zantac’s presence as a contaminant in generic Zyrtec is not detailed in the initial report. Unique Pharmaceutical Laboratories has not released a public statement regarding the recall as of the latest information available. The FDA has not provided further details on the implications of this specific contamination.
Story summarized from the original created by Joseph Swanson on www.fda.gov, see more information here.
